These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 34231261)

  • 21. Methylprednisolone alone or combined with cyclosporine or mycophenolate mofetil for the treatment of immune-mediated hemolytic anemia in dogs, a prospective study.
    Agnoli C; Tumbarello M; Vasylyeva K; Selva Coddè CS; Monari E; Gruarin M; Troìa R; Dondi F
    J Vet Intern Med; 2024; 38(5):2480-2494. PubMed ID: 38961558
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of treatment with a combination of mycophenolate mofetil and prednisolone in dogs with meningoencephalomyelitis of unknown etiology: a retrospective study of 86 cases (2009-2017).
    Song JH; Yu DH; Lee HC; Hwang TS; Kim YJ; An SJ; Jung DI
    BMC Vet Res; 2020 Jun; 16(1):192. PubMed ID: 32532259
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of canine meningoencephalomyelitis of unknown aetiology with mycophenolate mofetil and corticosteroids: 25 cases (2007-2012).
    Woolcock AD; Wang A; Haley A; Kent M; Creevy KE; Platt SR
    Vet Med Sci; 2016 May; 2(2):125-135. PubMed ID: 29067186
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A case of immune-mediated thrombocytopenia, possibly Evans syndrome, in a neutered Rottweiler dog.
    Apps C
    Can Vet J; 2023 Apr; 64(4):379-382. PubMed ID: 37008642
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An evaluation of the usefulness of mycophenolate mofetil in pemphigus.
    Powell AM; Albert S; Al Fares S; Harman KE; Setterfield J; Bhogal B; Black MM
    Br J Dermatol; 2003 Jul; 149(1):138-45. PubMed ID: 12890207
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients.
    Kuypers DR; de Jonge H; Naesens M; de Loor H; Halewijck E; Dekens M; Vanrenterghem Y
    Clin Ther; 2008 Apr; 30(4):673-83. PubMed ID: 18498916
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety assessment of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable renal transplant recipients.
    Massari P; Duro-Garcia V; Girón F; Hernández E; Juárez F; Castro C; Toledo M;
    Transplant Proc; 2005 Mar; 37(2):916-9. PubMed ID: 15848574
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mycophenolate mofetil for the treatment of children with immune thrombocytopenia and Evans syndrome. A retrospective data review from the Italian association of paediatric haematology/oncology.
    Miano M; Ramenghi U; Russo G; Rubert L; Barone A; Tucci F; Farruggia P; Petrone A; Mondino A; Lo Valvo L; Crescenzio N; Bellia F; Olivieri I; Palmisani E; Caviglia I; Dufour C; Fioredda F
    Br J Haematol; 2016 Nov; 175(3):490-495. PubMed ID: 27447678
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An intact microbiota is required for the gastrointestinal toxicity of the immunosuppressant mycophenolate mofetil.
    Flannigan KL; Taylor MR; Pereira SK; Rodriguez-Arguello J; Moffat AW; Alston L; Wang X; Poon KK; Beck PL; Rioux KP; Jonnalagadda M; Chelikani PK; Galipeau HJ; Lewis IA; Workentine ML; Greenway SC; Hirota SA
    J Heart Lung Transplant; 2018 Sep; 37(9):1047-1059. PubMed ID: 30173823
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mycophenolate mofetil (MMF) as therapy for refractory chronic GVHD (cGVHD) in children receiving bone marrow transplantation.
    Busca A; Saroglia EM; Lanino E; Manfredini L; Uderzo C; Nicolini B; Messina C; Rabusin M; Miniero R
    Bone Marrow Transplant; 2000 May; 25(10):1067-71. PubMed ID: 10828867
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Everolimus in combination with mycophenolate mofetil as pre- and post-transplantation immunosuppression after nonmyeloablative hematopoietic stem cell transplantation in canine littermates.
    Machka C; Lange S; Werner J; Wacke R; Killian D; Knueppel A; Knuebel G; Vogel H; Lindner I; Roolf C; Murua Escobar H; Junghanss C
    Biol Blood Marrow Transplant; 2014 Sep; 20(9):1301-6. PubMed ID: 24923538
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of mycophenolate mofetil intolerance on early results of kidney transplantation.
    Kahu J; Kyllönen L; Salmela K
    Transplant Proc; 2005 Oct; 37(8):3276-9. PubMed ID: 16298571
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mycophenolate mofetil and enteric-coated mycophenolate sodium in the treatment of pemphigus vulgaris and pemphigus foliaceus.
    Doukaki S; Platamone A; Alaimo R; Bongiorno MR
    J Dermatolog Treat; 2015 Feb; 26(1):67-72. PubMed ID: 24521072
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mycophenolic acid in patients with immune-mediated inflammatory diseases: From humans to dogs.
    Klotsman M; Sathyan G; Anderson WH; Garden OA; Shivanand P
    J Vet Pharmacol Ther; 2019 Mar; 42(2):127-138. PubMed ID: 30375004
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic polymorphisms influence mycophenolate mofetil-related adverse events in pediatric heart transplant patients.
    Ohmann EL; Burckart GJ; Brooks MM; Chen Y; Pravica V; Girnita DM; Zeevi A; Webber SA
    J Heart Lung Transplant; 2010 May; 29(5):509-16. PubMed ID: 20061166
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mycophenolate mofetil monotherapy in the management of paediatric uveitis.
    Chang PY; Giuliari GP; Shaikh M; Thakuria P; Makhoul D; Foster CS
    Eye (Lond); 2011 Apr; 25(4):427-35. PubMed ID: 21423146
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Retrospective analysis of immunosuppressive and anti-thrombotic protocols in nonassociative immune mediated hemolytic anemia in dogs.
    Weng J; Levy NA; Abbott HY; Mix JA; Wills RW; Mackin AJ; Thomason JM; Cridge H
    J Vet Intern Med; 2023 Mar; 37(2):528-536. PubMed ID: 36809664
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reasons for dose reduction of mycophenolate mofetil during the first year after renal transplantation and its impact on graft outcome.
    Vanhove T; Kuypers D; Claes KJ; Evenepoel P; Meijers B; Naesens M; Vanrenterghem Y; Cornelis T; Bammens B
    Transpl Int; 2013 Aug; 26(8):813-21. PubMed ID: 23746202
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Retrospective Study on the Safety and Efficacy of Leflunomide in Dogs.
    Sato M; Veir JK; Legare M; Lappin MR
    J Vet Intern Med; 2017 Sep; 31(5):1502-1507. PubMed ID: 28833582
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of mycophenolate mofetil as a rescue agent in the treatment of severe generalized myasthenia gravis in three dogs.
    Abelson AL; Shelton GD; Whelan MF; Cornejo L; Shaw S; O'Toole TE
    J Vet Emerg Crit Care (San Antonio); 2009 Aug; 19(4):369-74. PubMed ID: 25164637
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.